


## Upadacitinib tartrate

### Chemical Properties

CAS No. : 1607431-21-9  
 Formula: C<sub>21</sub>H<sub>33</sub>F<sub>3</sub>N<sub>6</sub>O<sub>11</sub>  
 Molecular Weight: 602.521  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



### Biological Description

Description	Upadacitinib is a potent and selective JAK inhibitor. Upadacitinib is approximately 74 fold selective for Jak1 over Jak2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models.
Targets(IC50)	Others,JAK

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6597 mL	8.2985 mL	16.597 mL
5 mM	0.3319 mL	1.6597 mL	3.3194 mL
10 mM	0.166 mL	0.8298 mL	1.6597 mL
50 mM	0.0332 mL	0.166 mL	0.3319 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. *Arthritis Rheumatol.* 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808. PubMed PMID: 27390150; PubMed Central PMCID: PMC5132065.
- Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. *Arthritis Rheumatol.* 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801. PubMed PMID: 27389975; PubMed Central PMCID: PMC5132116.
- Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. *Clin Pharmacokinet.* 2016 Dec;55(12):1547-1558. PubMed PMID: 27272171.
- Semerano L, Decker P, Clavel G, Boissier MC. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. *Expert Opin Investig Drugs.* 2016 Dec;25(12):1355-1359. PubMed PMID: 27748152.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481